ALZ-801 promotes amyloid clearance from brain
Milà-Alomà (2022) Nat Med; Hansson (2021) Nat Med, Karikari (2020) Lancet Neurol
Amyloid oligomers drive neurotoxicity & tau pathology
Injured neurons release misfolded tau protein that aggregates into tangles
Plasma p-tau181 reduction predicts clinical efficacy
Gantenerumab – AAIC 2022; Roche GRADUATE Phase 3 Studies Press Release, November 2022
Aducanumab – AAIC 2021 & CTAD 2021
Lecanemab – CTAD 2021; Swanson (2020) Alz Res Therapy; Eisai CLARITY AD Phase 3 Study Press Release, September 2022
ALZ-801 – CTAD 2022
Amyloid clearance from brain to plasma via astrocyte end-feet on capillaries & by glial uptake
Tarasof-Conway (2015) Nat Rev Neurol & Bagheri (2013) PLOS One
ALZ-801 blocks amyloid aggregation in brain, promotes efflux of monomers to plasma & activation of astrocytes
Tarasof-Conway (2015) Nat Rev Neurol & Bagheri (2013) PLOS One
Assay to measure neurotoxic amyloid oligomers in brain
- Alzheon collaborates with Czech Institute of Organic Chemistry & Biochemistry to develop commercial assay to measure neurotoxic amyloid oligomers in brain
- Diagnostic & theragnostic assay enables early intervention with ALZ-801
- Measurement of brain oligomer burden enables treatment & prevention:
- Monitoring of progress & assessment of treatment impact in patients
- Intervention years before emergence of clinical symptoms in cognitively normal individuals with increased risk for Alzheimer’s
Mass spectrometry detects soluble amyloid oligomers